3.06 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Briacell Therapeutics Corp. Common Shares
BCTXNASDAQ • USD
3.07
↗ 0.01 (0.23%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
3.07
↗ 0.01 (0.23%)
Market: CLOSED
Shares of Briacell Therapeutics Corp. Common Shares (BCTX) are trading at $3.08. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Jun 26, 2026.
Open?$2.96
High?$3.12
Low?$2.95
Prev. Close?$3.06
Volume?96.4K
Avg. Volume?264.2K
VWAP?$3.03
Rel. Volume?0.36x
Bid / Ask
Bid?$2.89 × 300
Ask?$3.20 × 200
Spread?$0.31
Midpoint?$3.05
Valuation & Ratios
Market Cap?26.6M
Shares Out?8.7M
Float?7.1M
Float %?97.5%
P/E Ratio?N/A
P/B Ratio?1.11
EPS?-$3.53
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
WEST VANCOUVER, A1 V7T 2X1
Phone: (604) 921-1810
WEST VANCOUVER, A1 V7T 2X1
Phone: (604) 921-1810
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?85
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.52Distress
Confidence?40%Low
Short InterestElevated
Short % of Float?5.33%Elevated
Short Interest?377.0K
Days to Cover?1.5
Free Float7.1M
Avg Daily Volume250.9K
Settlement Date2026-06-15
Financial Health
Current Ratio?7.07Strong
Quick Ratio?7.07Strong
Cash Ratio?1.92Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.11CHEAP▾
Peers100
S&P95
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.6CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-127.5%WEAK▾
S&P3
ROA?-113.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-30951946
Enterprise Value?$19.7M
Fundamentals ratios updated end of day